Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian equity markets continue in green
Mon, 25 Feb 11:30 am

Indian equity markets have continued in green during the previous two hours of trade. The most noticeable upward movements have been witnessed in the IT and auto sectors while realty and oil and gas have faced the maximum selling pressures.

The BSE Sensex is up by 45 points and NSE-Nifty is up by 13 points. BSE Mid Cap index is trading higher by 0.17% while BSE Small Cap index are trading lower by 0.02%. The rupee is trading at 54.12 to the US dollar.

Steel stocks are all trading in the green with Tayo Rolls and Adhunik Metals leading the gains. According to a leading financial daily, Steel Authority of India Ltd (SAIL) has lined up investments of Rs 103 bn to double its captive iron ore capacity to 45 m tonne. The biggest chunk of the investment, approximately amounting to Rs 65 bn has been earmarked for the Company's Rowghat mine in Chattisgarh and Gua mine in Jharkhand. The Rowghat mine is critical for serving the captive needs of SAIL's Bhilai Steel Plant. Production is expected to start within the next 2-3 years, however, Rowghat is an area prone to Maoist threats and the Union Government has agreed to deploy five battalions of CRPF and BSF personnel to counter any possible security threats. Approximately Rs 30 bn has been earmarked for investments in the Gua mines, where SAIL plans to set up a 4 m tonne pellet plant and a 10 m tonne benefaction unit to cater to the needs of IISCO Steel Plant at Burnpur. SAIL's stock is trading up by 0.46%.

Indian Pharma stocks are trading on a mixed note with Ranbaxy Labs and Panacea Biotech leading the gains while Cipla and Piramal Enterprises are leading the losses. According to a leading business daily, Ranbaxy has resumed production of its generic drug Lipitor for supply to the US market. The announcement comes after almost three and a half months when Ranbaxy had recalled the drug from the American retail market as it feared tiny glass particles to be included in the circulated drugs. Ranbaxy has stated that it has been working with US Food and Drug Administration (USFDA) to identify and implement multiple corrective and preventive actions. The drug, which in medical parlance is known as Atorvastatin earned close to US$50 m in the third quarter of 2012 and the Company is expecting to earn at least US$ 20-25 m in the fourth quarter of 2012. Ranbaxy's stock is trading up by 3.8%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian equity markets continue in green". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.